Bacil Pharma Ltd
- Market Cap ₹ 57.0 Cr.
- Current Price ₹ 39.8
- High / Low ₹ 61.8 / 26.7
- Stock P/E 36.6
- Book Value ₹ 17.3
- Dividend Yield 0.00 %
- ROCE 3.93 %
- ROE 6.21 %
- Face Value ₹ 10.0
Pros
- Company has reduced debt.
- Company is almost debt free.
Cons
- Though the company is reporting repeated profits, it is not paying out dividend
- Company has a low return on equity of 3.21% over last 3 years.
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Peer comparison
Healthcare Healthcare Pharmaceuticals & Biotechnology Pharmaceuticals
Quarterly Results
Figures in Rs. Crores
Profit & Loss
Figures in Rs. Crores
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| 0.11 | 0.13 | 0.17 | 0.29 | 0.26 | 0.18 | 0.16 | 0.16 | 0.17 | 0.19 | 0.25 | 0.25 | |
| Operating Profit | -0.11 | -0.13 | -0.17 | -0.29 | -0.26 | -0.18 | -0.16 | -0.16 | -0.17 | -0.19 | -0.25 | -0.25 |
| OPM % | ||||||||||||
| 0.08 | 0.06 | 0.17 | -3.42 | -0.07 | -0.12 | -0.07 | -3.70 | 0.07 | 0.13 | 0.66 | 1.24 | |
| Interest | 0.00 | 0.00 | 0.00 | 0.03 | 0.00 | 0.01 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Depreciation | 0.00 | 0.00 | 0.00 | 0.01 | 0.01 | 0.01 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Profit before tax | -0.03 | -0.07 | 0.00 | -3.75 | -0.34 | -0.32 | -0.23 | -3.86 | -0.10 | -0.06 | 0.41 | 0.99 |
| Tax % | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | -57.58% | |
| -0.03 | -0.07 | 0.00 | -3.75 | -0.34 | -0.32 | -0.24 | -3.86 | -0.10 | -0.06 | 0.40 | 1.56 | |
| EPS in Rs | -0.05 | -0.12 | 0.00 | -6.37 | -0.58 | -0.54 | -0.41 | -6.55 | -0.17 | -0.10 | 0.28 | 1.09 |
| Dividend Payout % | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Compounded Sales Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| TTM: | % |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | 38% |
| 5 Years: | 77% |
| 3 Years: | 131% |
| TTM: | 1300% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | 28% |
| 5 Years: | 40% |
| 3 Years: | 65% |
| 1 Year: | 5% |
| Return on Equity | |
|---|---|
| 10 Years: | 0% |
| 5 Years: | 2% |
| 3 Years: | 3% |
| Last Year: | 6% |
Balance Sheet
Figures in Rs. Crores
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Equity Capital | 6.53 | 6.53 | 6.53 | 6.53 | 6.53 | 6.53 | 6.53 | 6.53 | 6.53 | 6.53 | 13.97 | 13.97 |
| Reserves | -0.06 | -0.13 | -0.09 | -4.29 | -4.62 | -5.14 | -5.14 | -5.30 | -5.43 | -5.31 | 11.46 | 10.84 |
| 0.14 | 0.27 | 0.31 | 0.00 | 0.10 | 0.17 | 0.18 | 0.03 | 0.02 | 0.10 | 0.16 | 0.00 | |
| 0.02 | 0.02 | 0.02 | 2.51 | 2.55 | 2.55 | 2.52 | 0.01 | 0.01 | 0.01 | 0.02 | 2.58 | |
| Total Liabilities | 6.63 | 6.69 | 6.77 | 4.75 | 4.56 | 4.11 | 4.09 | 1.27 | 1.13 | 1.33 | 25.61 | 27.39 |
| 0.01 | 5.25 | 5.94 | 2.53 | 2.53 | 2.52 | 2.51 | 0.01 | 0.01 | 0.01 | 0.00 | 0.00 | |
| CWIP | 5.88 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Investments | 0.51 | 0.51 | 0.54 | 1.15 | 0.96 | 0.43 | 0.37 | 0.31 | 0.43 | 0.61 | 21.36 | 24.24 |
| 0.23 | 0.93 | 0.29 | 1.07 | 1.07 | 1.16 | 1.21 | 0.95 | 0.69 | 0.71 | 4.25 | 3.15 | |
| Total Assets | 6.63 | 6.69 | 6.77 | 4.75 | 4.56 | 4.11 | 4.09 | 1.27 | 1.13 | 1.33 | 25.61 | 27.39 |
Cash Flows
Figures in Rs. Crores
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 0.26 | 0.06 | 0.00 | 1.44 | -0.30 | -0.38 | -0.40 | -4.01 | -0.15 | 0.00 | 0.40 | 0.71 | |
| -0.33 | -0.05 | 0.02 | -1.20 | 0.28 | 0.39 | 0.53 | 3.81 | -0.12 | 0.08 | 0.34 | -2.38 | |
| 0.00 | 0.00 | 0.00 | 0.00 | -0.16 | -0.06 | -0.07 | 0.33 | 0.06 | -0.06 | 2.08 | -0.62 | |
| Net Cash Flow | -0.07 | 0.01 | 0.02 | 0.23 | -0.18 | -0.05 | 0.06 | 0.13 | -0.20 | 0.01 | 2.82 | -2.29 |
| Free Cash Flow | 0.24 | -3.21 | 0.00 | 1.14 | -0.30 | -0.38 | -0.40 | -4.01 | -0.15 | 0.00 | 0.40 | 0.71 |
| CFO/OP | -236% | -46% | 0% | -497% | 115% | 211% | 250% | 2,506% | 88% | 0% | -160% | -284% |
Ratios
Figures in Rs. Crores
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debtor Days | ||||||||||||
| Inventory Days | ||||||||||||
| Days Payable | ||||||||||||
| Cash Conversion Cycle | ||||||||||||
| Working Capital Days | ||||||||||||
| ROCE % | -0.45% | -1.05% | -1.49% | -6.01% | -8.47% | -2.80% | -5.75% | -7.07% | -12.61% | -13.11% | -0.97% | 3.93% |
Insights
In beta| Mar 2016 | Mar 2017 | Mar 2018 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|---|---|---|---|---|
| Number of Permanent Employees Number |
|
||||||||
| Number of Operational Branches/Offices Number |
|||||||||
| Stake in Associate Company (CNX Corporation Ltd) Percentage (%) |
|||||||||
Extracted by Screener AI
Documents
Announcements
-
Board Meeting Outcome for Outcome Of The Meeting Of The Board Held On 26Th June, 2026 Pursuant To Regulation 30 Of The SEBI (LODR) Regulations, 2015
4h - Board approved proposal to raise up to Rs 50 crore via rights, preferential, convertible or other modes.
- Closure of Trading Window 1d
-
Disclosures under Reg. 29(2) of SEBI (SAST) Regulations, 2011
1d - Manubhai Amrutlal Shah sold 3,94,893 Bacil Pharma shares, reducing stake to 10.02% on June 23-24, 2026.
- Disclosures under Reg. 29(2) of SEBI (SAST) Regulations, 2011 2d
-
Board Meeting Intimation for Intimation Of Board Meeting Pursuant To Regulation 29 Of The SEBI (LODR) Regulations, 2015
23 Jun - Board meeting on 26 June 2026 to consider preferential issue, rights issue, or other fund raising modes.
Annual reports
-
Financial Year 2025
from bse
-
Financial Year 2024
from bse
-
Financial Year 2023
from bse
-
Financial Year 2022
from bse
-
Financial Year 2021
from bse
-
Financial Year 2020
from bse
-
Financial Year 2019
from bse
-
Financial Year 2018
from bse
-
Financial Year 2017
from bse
-
Financial Year 2016
from bse
-
Financial Year 2015
from bse
-
Financial Year 2014
from bse
-
Financial Year 2013
from bse
-
Financial Year 2012
from bse
-
Financial Year 2011
from bse
Operational Status:[1]
Company is non operational for the past many years. It has not carried out any major business activity and management is considering diversifying their business activities and have deployed surplus funds as temporary loans and advances